The Alzheimer's Drug Discovery Foundation (ADDF) is inviting applications to its Prevention Beyond the Pipeline program. Through the program, grants will be awarded in support of comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Funding priorities identified by the foundation include:
Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) — Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, ADDF will support collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script.
Comparative Effectiveness Research — For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for re-purposing to treat Alzheimer's or related dementias due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. ADDF will consider funding research that generates an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect individuals from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology.
Cognitive Decline and Cognitive Reserve — Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.
Grants of up to $100,000 over a year will be awarded in support of epidemiological analysis and grants of up to $3 million over a variable number of years will be awarded for clinical trials.
Eligible applicants include researchers and clinicians at academic medical centers, universities, nonprofits, and biotechnology companies worldwide. Existing companies and new spinouts also are eligible, and industry partnerships are strongly encouraged.
Letters of Intent are due October 11. Upon review, selected applicants will be invited to submit a full proposal by November 8, 2019.
See the Alzheimer's Drug Discovery Foundation website for complete program details, eligibility criteria, and a link to the application portal.